Modern immunotherapy for kidney cancer
- 作者: Protsenko S.A1, Semenova А.I.1, Oganesyan A.P1, Anokhina E.M1, Novik A.V1,2
-
隶属关系:
- N.N. Petrov National Medical Research Center of Oncology
- St. Petersburg State Pediatric Medical University
- 期: 卷 26, 编号 7 (2019)
- 页面: 73-78
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312210
- DOI: https://doi.org/10.18565/pharmateca.2019.7.73-78
- ID: 312210
如何引用文章
详细
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
S. Protsenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Аnna Semenova
N.N. Petrov National Medical Research Center of Oncology
Email: mirannia@yandex.ru
PhD, Oncologist, Department of Chemotherapy and Innovative Technologies, Senior Reseracher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation
A. Oganesyan
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Anokhina
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Novik
N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
参考
- Ljungberg B., Bensalah K., Canfield S., et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-24. Doi: 10.1016/j. eururo.2015.01.005. PMID: 25616710.
- Moch H. WHO classification 2016 and first S 3 guidelines on renal cell cancer: What is important for the practice? Pathol. 2016;37(2):127-33.
- Zhang L., Yao L., Li X., Jewett M.A., He Z., Zhou L. Natural history of renal cell carcinoma: an immunohistochemical analysis of growth rate in patients with delayed treatment. J Formos Med Assoc. 2016;115:463-69.
- Crespigio J., Berbel L.C.L., Dias M.A., Berbel R.F., Pereira S.S., Pignatelli D., Mazzuco T.L. Von HippelLindau disease: a single gene, several hereditary tumors. J Endocrinol Invest. 2018;41:21-31.
- Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. PMID: 25220842.
- Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017. 250 с.
- Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2015;370:2103-11.
- Motzer R.J., et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol. 2015;33:1430-37.
- Motzer R.J., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.[
- Atkins M.B., et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 2017;35 (Suppl., Abstr. 4505).
- Choueiri T.K., et al. First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. J Clin Oncol. 2017;35(Suppl. Abstr. 4504).
- Chowdhury S., et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2017;35(Suppl., Abstr.4506).
- Escudier B., Tannir N.M., McDermott D., et al. CheckMate 214: efficacy and safety of nivolumab. ipilimumab (N.I) v sunitinib (S) for treatmentnaive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Ann Oncol. 2017;28(Suppl. 5).
- Schmidinger M. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. Curr Opin Urol. 2018;28(1):29-34. doi: 10.1097/MOU.0000000000000456. PMID: 29045250.
- Barata P.C., Rini B. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507-24. doi: 10.3322/caac.21411.
- Ross K., Jones R.J. Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci. (Lond) 2017;131(21):2627-42. Doi: 10.1042/ CS20160894. PMID: 29079639.
- Beckermann K.E., Johnson D.B., Sosman J.A. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol. 2017;13(1):77-84. doi: 10.1080/1744666X.2016.1214575.
- Poprach A., Lakomy R., Büchler T. Immunotherapy of renal cell carcinoma. Clin Onkol. 2017;30(Suppl. 3):55-61. doi: 10.14735/amko20 1 73S55. PMID: 29239194.
- Adapted from poster presented by E.R. Plimack et al. 15th International Kidney Cancer Symposium. November 4-5, 2016. Miami, FL, USA.
- Motzer R.J., Escudier B., McDermott D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13. doi: 10.1056/NEJMoa1510665. PMID: 26406148.
- Powles T., Staehler M., Ljungberg B., et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol. 2016;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. PMID: 26508312.
补充文件
![](/img/style/loading.gif)